Stephen R Byrn
Overview
Explore the profile of Stephen R Byrn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dayo Owoyemi B, Zeller M, Pereira da Silva B, Akinyemi A, Ando R, de Araujo G, et al.
Mol Pharm
. 2025 Jan;
22(2):1042-1060.
PMID: 39804247
Lumefantrine (LMF) is a low-solubility antimalarial drug that cures acute, uncomplicated malaria. It exerts its pharmacological effects against erythrocytic stages of spp. and prevents malaria pathogens from producing nucleic acid...
2.
Byrn S
Pharm Res
. 2024 Aug;
41(8):1547-1555.
PMID: 39107515
This paper reviews the accelerated development of pharmaceuticals, exploring past, present, and future perspectives. It provides a historical overview of early strategies used to expedite development, beginning with initiatives from...
3.
Wilke S, Al-Rubkhi A, Benmore C, Byrn S, Weber R
Mol Pharm
. 2024 Jul;
21(8):3967-3978.
PMID: 39018110
The metastability of amorphous formulations poses barriers to their safe and widespread commercialization. The propensity of amorphous solid dispersions (ASDs) to crystallize is directly linked to their molecular structure. Amorphous...
4.
Okezue M, Uche C, Adebola A, Byrn S
AAPS PharmSciTech
. 2024 Jul;
25(6):152.
PMID: 38954218
Bedaquiline (BQ) solid lipid nanoparticles (SLNs), which have previously been formulated for parenteral administration, have a risk of patient non-compliance in treating tuberculosis. This research presents a strategy to develop...
5.
Wilke S, Benmore C, Menon V, Smith D, Byrn S, Weber R
RSC Pharm
. 2024 Apr;
1(1):121-131.
PMID: 38646594
Amorphous solid dispersions (ASDs) are a widely studied formulation approach for improving the bioavailability of poorly water-soluble pharmaceuticals. Yet, a complete understanding remains lacking for how specific processing methods may...
6.
Okezue M, Byrn S, Probost J, Lucas M, Clase K
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256876
Levothyroxine tablets, although highly prescribed in the United States, have been one of the most frequently recalled products. Because of the importance of the medication, several efforts have been put...
7.
Okezue M, Byrn S
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259402
Bedaquiline has been approved as a combination therapy to treat multi-drug-resistant tuberculosis in adults ≥ 18 years old. The citrate, fumarate, phosphate, and tartrate salts have obtained patents, but the...
8.
de Assis J, Barbosa E, Bezzon V, Lourenco F, Carvalho F, Matos J, et al.
Int J Pharm
. 2022 Jan;
614:121456.
PMID: 35017024
The FDA-approved anthelmintic flubendazole has shown potential to be repositioned to treat cancer and dry macular degeneration; however, its poor water solubility limits its use. Amorphous solid dispersions may overcome...
9.
Kerstiens E, Byrn S, Clase K
AAPS PharmSciTech
. 2021 Dec;
23(1):19.
PMID: 34904204
Pharmaceutical companies use the quality by design (QbD) approach to build high-quality drug products. A thorough understanding of risk factors is required to successfully employ QbD. In order to better...
10.
Zeller M, Bogdanowich-Knipp S, Smith P, Purcell D, Okezue M, Smith D, et al.
Acta Crystallogr E Crystallogr Commun
. 2021 May;
77(Pt 4):433-445.
PMID: 33936772
Bedaquiline is one of two important new drugs for the treatment of drug-resistant tuberculosis (TB). It is marketed in the US as its fumarate salt, but only a few salts...